当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
BEXSERO, Meningococcal Group B Vaccine
申请企业
GlaxoSmithKline Biologicals
药品名称
BEXSERO, Meningococcal Group B Vaccine
承诺描述
A deferred pediatric study (V72_57) under PREA to evaluate the safety and immunogenicity of BEXSERO in North American infants 6 weeks through 12 months of age for the prevention of invasive group B meningococcal disease.